Company intelligence / Profile preview

20n Bio

Malvern (Greater Philadelphia region), Pennsylvania, United States20n.bio ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

20n Bio has developed a proprietary platform for the rapid discovery and optimization of cyclic peptide therapeutics. The company is leveraging this technology to build an internal pipeline and has established partnerships by licensing early-stage hits. No clinical results have been published as programs are preclinical[1][2].

Therapeutic areas: OncologyMetabolic Disorders
Modalities: Cyclic peptidesPeptide-drug conjugatesOral peptidesRadioligand therapy (peptide-based)
Industry: Biotech

Partnerships

Pharmaceutical and biotechnology companies via licensing early hits and providing customized solutions, but no specific partners named publicly[1].

Beyond the preview

Go deeper on 20n Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 20n Bio.

Explore the full profile